The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...
At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...
CDC officials say medical professionals are seeing more patients whose illness cannot be traced back to an infected animal or ...
The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.